Healthcare entity
All 1 tracked stories fall under one category: regulation. Of the tracked stories, 1 of 1 also mention MHRA, the most common co-covered peer. Each carries 3 original sources on average. We currently track 1 Healthcare story that mention OASIS 4 trial, all published on June 11, 2026.
Last mentioned: Jun 11, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: regulation. Of the tracked stories, 1 of 1 also mention MHRA, the most common co-covered peer. Each carries 3 original sources on average. We currently track 1 Healthcare story that mention OASIS 4 trial, all published on June 11, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 3 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering OASIS 4 trial. Shared-story counts are live from our verified record — not editorial picks.
The MHRA’s landmark approval of oral semaglutide introduces a needle-free GLP-1 option for obesity, backed by a 17% weight-loss result in adherent patients. Healthcare providers must now navigate private-only access and patient education around strict dosing protocols.
Source: investegate.co.uk · manilatimes.net
OASIS 4 trial is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
